Last reviewed · How we verify
NCT04716920
Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial
NA trial testing Tai Chi in Anatomic Stage I Breast Cancer AJCC v8 in 39 participants. Completed in 23 December 2021.
21 July 2021
Quick facts
| Lead sponsor | Thomas Jefferson University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 39 |
| Start date | 11 March 2020 |
| Primary completion | 21 July 2021 |
| Estimated completion | 23 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tai Chi
- FitBit
- Support Group Therapy
- Questionnaire Administration
- Quality-of-Life Assessment
Conditions studied
- Anatomic Stage I Breast Cancer AJCC v8 — all drugs for Anatomic Stage I Breast Cancer AJCC v8 →
- Anatomic Stage IA Breast Cancer AJCC v8 — all drugs for Anatomic Stage IA Breast Cancer AJCC v8 →
- Anatomic Stage IB Breast Cancer AJCC v8 — all drugs for Anatomic Stage IB Breast Cancer AJCC v8 →
- Anatomic Stage II Breast Cancer AJCC v8 — all drugs for Anatomic Stage II Breast Cancer AJCC v8 →
Sponsor
Thomas Jefferson University
Who can join
18 and older, female only, with Anatomic Stage I Breast Cancer AJCC v8 or Anatomic Stage IA Breast Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies new methods using Tai Chi for the relief of joint pain (arthralgia) caused by an aromatase inhibitor in patients with stage I-III breast cancer. Tai Chi is a mind-body therapy that integrates moderate physical activity, deep breathing and meditation. Tai Chi may help to reduce aromatase inhibitor-induced joint pain, and offer a promising approach to managing symptoms in cancer patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Hyder T, Marino CC, Ahmad S, Nasrazadani A, et al · · 2021 · cited 67× · PMID 34385978 · DOI 10.3389/fendo.2021.713700 -
A Telehealth-Delivered Tai Chi Intervention (TaiChi4Joint) for Managing Aromatase Inhibitor-Induced Arthralgia in Patients With Breast Cancer During COVID-19: Longitudinal Pilot Study.
Gomaa S, West C, Lopez AM, Zhan T, et al · · 2022 · cited 15× · PMID 35727609 · DOI 10.2196/34995
Verify or expand the search:
- PubMed search for NCT04716920
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tai Chi
Trials testing the same drug.
- NCT07480174 — Effects of Tai Chi and Yoga on Flexibility, Anxiety, and Sleep Quality in Women · NA · recruiting
- NCT07341802 — Pilot Feasibility Study of a Fall Prevention Exercise Programme for Community-dwelling Older Adults in Nanchang, China · NA · recruiting
- NCT07461987 — Tai Chi and Square-Stepping Exercises in Women With Multiple Sclerosis · NA · recruiting
- NCT07512739 — A Sitting Tai Chi Programme for Chronic Stroke Survivors With Post-stroke Cognitive Impairment · NA · recruiting
- NCT07113444 — Acute Effect of Tai Chi Versus Moderate-Intensity Combined Exercise on Cardiovascular, Metabolic, and Cardiac Autonomic · NA · not yet recruiting
Other recruiting trials for Anatomic Stage I Breast Cancer AJCC v8
Currently open trials in the same condition.
- NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
- NCT07158021 — Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial · Phase 2 · recruiting
- NCT06324240 — Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc · Phase 1 · recruiting
- NCT07407920 — Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · Phase 2 · active not recruiting
- NCT06876714 — ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol · Phase 3 · recruiting
Other Thomas Jefferson University trials
Trials by the same sponsor.
- NCT07526480 — Improving Dementia Care in Primary Practice · NA · not yet recruiting
- NCT07414550 — Radiotherapy for Refractory Hidradenitis Suppurativa · NA · not yet recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07217197 — Respiratory Monitoring System That Detects & Predicts OIRD · NA · enrolling by invitation
- NCT07145099 — The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04716920 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thomas Jefferson University
- Last refreshed: 29 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04716920.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing